Search

Search Constraints

You searched for: Subject interstitial fibrosis

Search Results

1. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. Issue 1 (25th March 2019)

2. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). Issue 1 (30th December 2021)

3. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. Issue 1 (15th January 2021)

4. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. Issue 1 (20th January 2022)

5. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. Issue 1 (17th May 2020)

6. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. Issue 1 (17th May 2020)

7. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. Issue 1 (17th May 2020)

8. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. Issue 1 (5th July 2020)

9. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. Issue 1 (17th May 2020)

10. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. Issue 1 (5th July 2020)